benjamin philip levy, md, on tumor mutation burden (tmb) as a biomarker in nsclc
Published 6 years ago • 63 plays • Length 1:20
Download video MP4
Download video MP3
Similar videos
-
1:38
benjamin philip levy, md, on options for nsclc patients who progress on 1st line i-o & chemotherapy
-
1:25
tumor mutational burden (tmb): a predictive biomarker for lung cancer immunotherapy response
-
3:20
howard (jack) west, md, regarding tumor mutation burden (tmb) as a biomarker for nsclc patients
-
1:14
dr. levy on investigational biomarkers of response to immunotherapy in nsclc
-
1:16
dr. levy on positive and negative biomarkers for immunotherapy in lung cancer
-
1:19
benjamin philip levy, md, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab
-
1:27
benjamin philip levy, md, regarding combo chemotherapy & immunotherapy in 2nd line nsclc
-
4:37
dr. ben levy: the mission is to lead
-
1:40
benjamin philip levy, md, offers opinion on testing for pdl-1 expression in nsclc
-
2:10
benjamin philip levy, md, comments on the impower150 clinical trial in nsclc
-
9:09
tumor mutational burden in sclc: a valuable immunotherapy biomarker? (bmic-011)
-
2:04
dr. levy on biomarkers of response to immunotherapy
-
3:22
lung cancer immunotherapy response testing: pdl-1, tmb or an alternative?
-
1:15
benjamin levy on advances in diagnosing lung cancer
-
12:37
benjamin p. levy, md: the challenges of tissue for lung cancer patients
-
1:02
dr. levy discusses the outlook for oncogene-driven nsclc
-
1:11
dr. hellmann on tumor mutational burden testing in patients with lung cancer
-
7:16
benjamin p. levy, md: next generation sequencing in lung cancer
-
8:34
emerging biomarkers for lung cancer
Clip.africa.com - Privacy-policy